Asymchem 2026 Half-Year Report (A-Share): Revenue RMB 3.607B, Up 13.13%; Net Profit RMB 520M, Down 15.71%; Full-Year Guidance +19%–22%
H1 revenue RMB 3.607B (+13.13% YoY); net profit attributable to shareholders RMB 520M (-15.71%); deduct-non-recurring net profit RMB 525M (-7.30%); operating cash flow RMB 822M (+17.18%); total assets RMB 20.83B, net assets RMB 17.74B; no dividend. Full-year 2026 revenue guided to grow 19%–22%.
On 24 August 2026, Asymchem Pharmaceutical Group (Tianjin) Co., Ltd. (002821.SZ / 06821.HK) released its 2026 semi-annual report (A-share). Revenue reached RMB 3.607B, up 13.13% YoY; net profit attributable to shareholders was RMB 520M, down 15.71% YoY; deduct-non-recurring net profit was RMB 525M, down 7.30%. For context, the HK interim report disclosed on 11 August showed H1 revenue of RMB 3.188B and profit of RMB 617M — A-share and HK figures differ slightly due to consolidation scope and accounting presentation, but both reflect steady top-line growth with near-term profit pressure.
Profit quality and balance sheet remained sound: net operating cash flow was RMB 822M, up 17.18% YoY; basic EPS RMB 1.45 (-13.69%); weighted ROE 2.91% (-0.68 ppt); period-end total assets RMB 20.83B (+2.73% vs. prior year-end) and net assets attributable to shareholders RMB 17.74B (+0.59%). The company plans no cash dividend, no bonus shares and no capitalisation of reserves. At period-end the common-shareholder count was 51,711; the largest shareholder ASYMCHEM LABORATORIES, INCORPORATED held 31.91% and HAO HONG held 3.95%, with both controlling shareholder and actual controller unchanged.
On the business front, the company positions itself as a globally leading one-stop CDMO solutions provider. Building on its small-molecule strength, it is advancing chemical macromolecules, biologics, drug product, clinical research services, synthetic biology and new-technology export in concert. With the CDMO sector showing positive momentum in 2026, Asymchem continues to invest heavily in incremental modalities — peptides, oligonucleotides and ADC — consistent with its earlier expansion cadence: chemical macromolecules (peptide/oligonucleotide TIDES) exceeded RMB 1B revenue in 2025 (doubling YoY), and peptide solid-phase capacity is planned to rise from 45,000 L to 69,000 L by end-2026.
Orders and full-year outlook: the company noted that relevant orders typically concentrate in H2 delivery, and therefore guides full-year 2026 revenue to grow 19%–22%. Although Q1 attributable net profit fell 6.82% YoY, Q2 completed a bottom-up inflection. That said, peptide commercial orders have long cycles and uneven revenue recognition, and with overseas customers making up a high share of revenue, geopolitical policy shifts and customer capex cuts remain potential headwinds.